PPT-Adherence and Acceptability for PrEP formulations

Jessica Haberer MD MS July 24 2017 Conflicts of Interest I have no conflicts to declare Grant funding US National Institutes of Health Bill and Melinda Gates Foundation USAID Consultation US National Institutes of Health World Health Organization Merck. Daniel Yang, MD Candidate*. Fogarty International Clinical Research Scholar. Research Institute for Health Sciences Institute (CMU). Johns Hopkins Bloomberg School of Public Health. International AIDS Conference. of the evidence from oral and topical . PrEP. efficacy . trials. What . we know and what we still need to . know.. Javier R. Lama, MD, MPH. Director. , HIV Prevention Intervention Studies. IMPACTA PERU Clinical Trials . Providers in Clinical Settings. 2. Welcome!. Please sign the registration sheet.. Please make a name tag for yourself.. Please take a participant’s folder. . Any component of this document may be reproduced or adapted without prior permission from ICAP, provided that: 1) ICAP is acknowledged; 2) appropriate attribution is given for all changes that are made; and 3) the material is made available free of charge. . B. Wamuti. , J. Odoyo, B. Rono, C. Cohen, E. Bukusi. . Kenya Medical Research Institute. University of Washington. University of California, San Franscisco . . Adherence crucial for success of any clinical drug trial and/or treatment. Robert M. Grant, M.D., M.P.H. .. IAS 2017, July 2017, Paris. Disclosures. Gilead Sciences donated study medication to US NIH for trials that I have led, including . iPrEx. , . iPrEx. OLE, and HPTN 067.. Module . 1(b). The Evidence in Detail. Session Overview. Seroconversion rates. PrEP. Studies: MSM, transgender population, women, discordant couples. Benefits of . PrEP. Barriers to . PrEP. services. Oral . PrEP. in MSM. Division of Global HIV and TB, CDC, New Delhi, India. Timothy H. . Holtz . (CDC/DHAP / Thailand MOPH – US CDC Collaboration). and HPTN . 067/ADAPT Study . Team. MOSY08, IAS. , . Katherine Marx, MS, MPH, FNP-BC. June 2014. Disclosure. I, Katherine Marx, have no relevant financial, professional, or personal relationships to disclose.. Objectives. Know current US recommendations for . PrEP. Version. : December . 2018. Outline of training. Module 1: Introduction to oral PrEP. Oral PrEP: the basics. What is combination prevention?. How effective is oral PrEP? . What are the differences among PrEP, PEP, and ART? . (Version 2.0). 2. Welcome!. Please sign the registration sheet.. Please make a name tag for yourself.. Please ta. ke a participant . manual, notebook, and pen. . Any component of this document may be reproduced or adapted without prior permission from ICAP, provided that: 1) ICAP is acknowledged; 2) appropriate attribution is given for all changes that are made; and 3) the material is made available free of charge. . PrEP Training for Providers in Clinical Settings (Version 2.0) 2 Welcome! Please sign the registration sheet. Please make a name tag for yourself. Please ta ke a participant manual, notebook, and pen. HPTN 082: Evaluation of daily oral PrEP as a primary prevention strategy for young African women Connie Celum and Sinead Delany- Moretlwe HPTN 082/HERS co-chairs How do you create demand? What information is needed? U. sers. . W. ho. Test Positive for HIV. Jean-Michel Molina, . MD. University . of . Paris and . Saint-Louis . Hospital, INSERM U944, France. HIV testing and Management in the Era of PrEP. Disclosures. PrEP Counseling Center. What is Medication Adherence?. The World Health Organization defines medication adherence as the degree to which the person’s behavior corresponds with the agreed recommendations from a health care provider..